

10. The salt as claimed in claim 1 or 2, characterized in that it is the potassium salt of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid.
- 5 11. The salt as claimed in claim 10, characterized in that the X-ray diffractogram of the compound has a peak maximum of the 2 theta angle at 23.7.
12. The salt as claimed in claim 10 or 11, characterized in that the X-ray diffractogram of the compound has peak maxima of the 2 theta angle at 23.7, 15.3 and 20.5.
13. The salt as claimed in any of claims 1 to 12 for the treatment of disorders.
- 10 14. A medicament comprising a salt as claimed in any of claims 1 to 12 and no greater proportions of any other form of the compound of the formula (I).
15. A medicament comprising a compound according to any of Claims 1 to 12 in more than 90 percent by weight based on the total amount of the compound of the formula (I) present.
- 15 16. A process for preparing the compound as claimed in any of claims 1 to 12, which comprises dissolving the compound of the formula (I) in the form of the free acid for example in an inert solvent and stirring or shaking with a solution of the salt-forming base at a temperature of 10°C to 60°C.
17. The use of a compound as claimed in any of claims 1 to 12 for producing a medicament for treatment and/or prophylaxis of cardiovascular, inflammatory, allergic and/or fibrotic disorders.
18. A method for treatment of cardiovascular disorders by administering an effective amount of a compound as claimed in any of claims 1 to 12.

10. The salt as claimed in claim 1 or 2, characterized in that it is the potassium salt of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid.
- 5 11. The salt as claimed in claim 10, characterized in that the X-ray diffractogram of the compound has a peak maximum of the 2 theta angle at 23.7.
12. The salt as claimed in claim 10 or 11, characterized in that the X-ray diffractogram of the compound has peak maxima of the 2 theta angle at 23.7, 15.3 and 20.5.
13. The salt as claimed in any of claims 1 to 12 for use in the treatment of disorders.
- 10 14. A medicament comprising a salt as claimed in any of claims 1 to 12 and no greater proportions of any other form of the compound of the formula (I).
15. A medicament comprising a compound according to any of Claims 1 to 12 in more than 90 percent by weight based on the total amount of the compound of the formula (I) present.
- 15 16. A process for preparing the compound as claimed in any of claims 1 to 12, which comprises dissolving the compound of the formula (I) in the form of the free acid for example in an inert solvent and stirring or shaking with a solution of the salt-forming base at a temperature of 10°C to 60°C.
17. The use of a compound as claimed in any of claims 1 to 12 in the manufacture of a medicament for the treatment and/or prophylaxis of cardiovascular, inflammatory, allergic and/or fibrotic disorders.